Advertisement

Evaluation of Multimodality Management of Adenoid Cystic Carcinoma of the Head and Neck

  • Amit Bahl
  • Naresh Kumar Panda
  • Arun Elangovan
  • Jaimanti Bakshi
  • Roshan Verma
  • Satyawati Mohindra
  • Rijuneeta Gupta
  • Arun Singh Oinam
  • Satinder Kaur
  • R. K. Vashishta
  • Sushmita Ghoshal
Original Article
  • 19 Downloads

Abstract

Adenoid cystic carcinoma is a relatively rare tumour arising from salivary glands of head and neck region. Surgery and radiotherapy form standard treatment modalities in the management of this tumor. In this analysis we present results of multimodality treatment in our cohort of patient. This retrospective analysis evaluated results of treatment in forty patients diagnosed with adenoid cystic carcinoma of the head and neck. Evaluation was done to identify prognostic factors affecting the disease free survival. A median disease free survival of 34 ± 2.42 (Median ± SE) versus 10 ± 5.45 months was seen in patients undergoing surgery followed by post operative radiotherapy versus radiotherapy alone (P = 0.01). A radiotherapy dose more than 60 Gy was associated with a better disease free survival compared with patients receiving less than 60 Gy (P = 0.01). Positive surgical margins and perineural invasion were associated with a poor treatment outcome (P = 0.02) Patients with c-kit positive status showed a poor local control rate (P = 0.05).

Keywords

Adenoid cystic Cancer Head and neck Radiotherapy Imatinib 

Notes

Compliance with Ethical Standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in the study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Gomez DR, Hoppe BS, Wolden SL et al (2008) Outcomes and prognostic variables in adenoid cystic carcinoma of head and neck: a recent experience. Int J Radiat Oncol Biol Phys 70:1365–1372CrossRefPubMedGoogle Scholar
  2. 2.
    Coco- Pelaz A, Rodrigo JP, Bradley PJ et al (2015) Adenoid cystic carcinoma of head and neck- an update. Oral Oncol 51:652–661CrossRefGoogle Scholar
  3. 3.
    Chen AM, Bucci MK, Weinberg V et al (2006) Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys 66:152–159CrossRefPubMedGoogle Scholar
  4. 4.
    Cordesmeyer R, Schliephake H, Kauffmann P et al (2017) Clinical prognostic factors of salivary adenoid cystic carcinoma: a single-center analysis of 61 patients. J Craniomaxillofac Surg 45:1784–1787CrossRefPubMedGoogle Scholar
  5. 5.
    Ali S, Palmer FL, Katabi N et al (2017) Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation. Laryngoscope 127:2265–2269CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Nakano K, Sato Y, Sasaki T et al (2016) Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses. Acta Otolaryngol 136:948–951CrossRefPubMedGoogle Scholar
  7. 7.
    Kim Y, Lee SJ, Lee JY et al (2017) Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean Cancer Study Group HN14-01). Cancer 123:1958–1964CrossRefPubMedGoogle Scholar
  8. 8.
    Papaspyrou G, Hoch S, Rinaldo A et al (2011) Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head andneck: a review. Head Neck 33:905–911CrossRefPubMedGoogle Scholar
  9. 9.
    Hotte SJ, Winquist EW, Lamont E et al (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary gland expressing c-kit: a Princess Margret Hospital phase II consortium study. J Clin Oncol 23:585–590CrossRefPubMedGoogle Scholar
  10. 10.
    Kokemueller H, Eckardt A, Brachvogel P et al (2004) Adenoid cystic carcinoma of the head and neck: a 20 years experience. Int J Oral Maxillofac Surg 33:25–31CrossRefPubMedGoogle Scholar
  11. 11.
    Silverman DA, Carlson TP, Khuntia D et al (2004) Role of postoperative radiotherapy in adenoid cystic carcinoma of head and neck. Laryngoscope 114:1194–1199CrossRefPubMedGoogle Scholar
  12. 12.
    Takebayashi S, Shinohara S, Tamaki H et al (2018) Adenoid cystic carcinoma of the head and neck: a retrospective multicenter study. Acta Otolaryngol 38:73–79CrossRefGoogle Scholar
  13. 13.
    Fordice J, Kershaw C, El-Naggar A et al (1999) Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 125:149–152CrossRefPubMedGoogle Scholar
  14. 14.
    Dillon PM, Chakraborty S, Moskaluk CA et al (2016) Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck 38:620–627CrossRefPubMedGoogle Scholar
  15. 15.
    Mino M, Pilch BZ, Faquin MD (2003) Expression of KIT (CD117) in neoplasm of the head and neck:an ancillary marker for adenoid cystic carcinoma. Mod Pathol 16:1224–1231CrossRefPubMedGoogle Scholar
  16. 16.
    Marcucci G, Perrotti D, Caligiuri MA (2003) Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Clin Cancer Res 9:1248–1252PubMedGoogle Scholar
  17. 17.
    Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625CrossRefPubMedGoogle Scholar
  18. 18.
    Faivre S, Raymond E, Casiraghi O et al (2005) Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 23:6271–6273CrossRefPubMedGoogle Scholar

Copyright information

© Association of Otolaryngologists of India 2018

Authors and Affiliations

  • Amit Bahl
    • 1
  • Naresh Kumar Panda
    • 2
  • Arun Elangovan
    • 1
  • Jaimanti Bakshi
    • 2
  • Roshan Verma
    • 2
  • Satyawati Mohindra
    • 2
  • Rijuneeta Gupta
    • 2
  • Arun Singh Oinam
    • 1
  • Satinder Kaur
    • 1
  • R. K. Vashishta
    • 3
  • Sushmita Ghoshal
    • 1
  1. 1.Department of Radiation OncologyPost Graduate Institute of Medical Education and ResearchChandigarhIndia
  2. 2.Departments of OtolaryngologyPost Graduate Institute of Medical Education and ResearchChandigarhIndia
  3. 3.Department of HistopathologyPost Graduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations